PubMed HealthSearch

Biomedical subjects

M Burkard

Publications and source records attributed to M Burkard.

3 recordsLinked to original sources

[Dyslipoproteinemia and diabetes mellitus in a metabolic syndrome].

AIMS: Presentation of important aspects of the metabolic syndrome, taking diabetes mellitus and the metabolic status in advanced age as an example. MAIN TOPICS: The metabolic syndrome represents a combination of diabetes mellitus, dyslipoproteinemia, adiposity, hypertension, and hyperuricemia, together with the sequelae of atherosclerosis, fatty liver and gallstones. In industrialized countries it is considered the most common metabolic sequela of affluence. Owing to the complexity of the disorders presenting, treatment must not be limited to normalization of glucose metabolism. In addition to dietetic and physiotherapeutic measures and anti-diabetic agents, treatment with lipid-lowering agents is also necessary. Since a main feature of disordered lipid metabolism, is hypertriglyceridemia, fibrates in particular are indicated. These lower not only the triglycerides, but also elevated fibrinogen levels, and, in the case of fenofibrate, uric acid levels. Glucose tolerance remains unaffected.

Diabetes Mellitus

Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation.

The effect of the lipid lowering drug etofibrate was investigated on lipid peroxidation as well as on cholesterol level. Rabbits were given a 0.1% cholesterol containing diet. Total cholesterol, LDL-cholesterol, triglycerides and lipid peroxidation, expressed as thiobarbituric acid reactive products, were determined. Treatment with etofibrate led to a marked decrease in total cholesterol and LDL-cholesterol. Furthermore, Cu(2+)-induced lipid peroxide formation was reduced in etofibrate treated rabbits. These results could be confirmed in a human study when patients with moderate hypercholesterolaemia were treated with etofibrate (2 x 500 mg/day) for a period of eight weeks. It could be shown that the onset of lipid peroxidation was remarkably increased, an effect which was completely reversible. Thus, etofibrate is effective not only in lowering plasma cholesterol but also in rendering LDL less susceptible to oxidation.

Animals